• But I think it is worth looking at this notion of being able to give relatively nontoxic, low-dose, continuous chemotherapy-which, I think, has at least a dual mode of action: the direct anti-tumor effects of the capecitabine itself and, it would appear, a vasculotoxic effect from giving chemotherapy in this way. (medscape.com)
  • We have not really had a simple, well-tolerated maintenance treatment to give, but one wonders that if we are reducing dose-intense chemotherapy to 3 months, whether there might be call for a trial looking at 3 months of intensive, FOLFOX/CAPOX-type adjuvant chemotherapy followed by a metronomic low-dose of chemotherapy and randomizing between the two. (medscape.com)
  • Maximum tolerated dose (MTD) chemotherapy followed by metronomic chemotherapy (low doses given on a frequent schedule) acts on tumour vascular endothelial cells by increasing the anti-tumour effect of anti-angiogenic agents. (nih.gov)
  • The scientific basis for metronomic chemotherapy is that conventional anti‑neoplastic drugs target vascular endothelial cell proliferation but the anti‑angiogenetic effect cannot be sustained because endothelial cells get a chance to recover during treatment breaks and this may be overcome by frequent treatment at low doses. (medicineplexus.com)
  • anti-angiogenic actions of metronomic chemotherapy, which inhibit the production of growth factors at the source. (medicineplexus.com)
  • In contrast, metronomic chemotherapy damages the source of these growth factors, namely, fibroblasts and TECs. (medicineplexus.com)
  • Therefore, while metronomic chemotherapy and anti-angiogenic drugs can both induce anti-angiogenesis, the underlying mechanisms are different, with metronomic therapy potentially having more lasting effects due to its targeting the source of vascular growth factors rather than the growth factors themselves. (medicineplexus.com)
  • Metronomic chemotherapy is the chronic administration of chemotherapy at low, minimally toxic doses on a frequent schedule of administration, with no prolonged drug-free breaks. (medicineplexus.com)
  • This multicentre, phase 2 study investigated the effectiveness of MTD gemcitabine combined with metronomic capecitabine plus the multikinase inhibitor sorafenib for the treatment of metastatic renal-cell carcinoma (RCC). (nih.gov)
  • Treatment consisted of intravenous gemcitabine 1000 mg/m(2) (days 1 and 8), oral capecitabine 500 mg/m(2) twice a day (final dose after adjustment, days 1-14), and oral sorafenib 400 mg twice a day (days 1-21), for six cycles, followed by sorafenib monotherapy (at the investigator's discretion if clinical benefit was maintained). (nih.gov)
  • Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study. (cancer.org)
  • 16. Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. (nih.gov)
  • A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial. (cdc.gov)
  • The other idea the study explored was a randomized comparison of single-agent bevacizumab vs metronomic capecitabine. (medscape.com)
  • Those who had not progressed-responding patients with stable disease-were randomly assigned to receive maintenance treatment with single-agent bevacizumab or low-dose capecitabine, at 500 mg twice daily, administered continuously. (medscape.com)
  • They had decent follow-up, and the data showed that progression-free and overall survival were indistinguishably similar between very low-dose capecitabine and single-agent bevacizumab. (medscape.com)
  • Results from an international phase 2 study show that using metronomic capecitabine in combination with the tyrosine kinase inhibitor pyrotinib continued to have promising efficacy results for patients with HER2-positive metastatic breast cancer. (targetedonc.com)
  • Metronomic anti-cancer therapy - an ongoing treatment option for advanced cancer patients. (hoajonline.com)